scholarly journals Heart transplantation in the new era of extended donor criteria

2021 ◽  
Author(s):  
Antonio Piperata ◽  
Raphael Caraffa ◽  
olimpia bifulco ◽  
Martina Avesani ◽  
Gino Gerosa ◽  
...  
Keyword(s):  
Heart Transplantation ◽  
Medical Community ◽  
Organ Shortage ◽  
New Era ◽  
High Incidence ◽  
Primary Graft Failure ◽  
End Stage Heart Failure ◽  
End Stage ◽  
Donor Criteria ◽  
Extended Donor Criteria

The heart transplantation (HT) is undoubtedly the best treatment for end-stage heart failure patients (2). However, the organ shortage remains a major challenge in cardiac surgery. Facing this problem, the medical community starts to extend the donor criteria to select more suitable organs for HT. The use of ECDs is still controversial, since it is associated with a high incidence of primary graft failure (3), and although it guarantees longer survival than without transplantation, there is still some hesitation in accepting this practice.

scholarly journals Heart transplantation in the new era of extended donor criteria

2021 ◽  
Author(s):  
Antonio Piperata ◽  
Raphael Caraffa ◽  
Olimpia Bifulco ◽  
Martina Avesani ◽  
Gino Gerosa ◽  
...  
Keyword(s):  
Heart Transplantation ◽  
New Era ◽  
Donor Criteria ◽  
Extended Donor Criteria

Coronary sinus catalase and ceruloplasmin levels predict all-cause mortality in patients with end-stage heart failure awaiting heart transplantation

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
W Szczurek ◽  
M Gasior ◽  
M Skrzypek ◽  
G Kubiak ◽  
A Kuczaj ◽  
...  
Keyword(s):  
Heart Failure ◽  
Heart Transplantation ◽  
Coronary Sinus ◽  
Public Institution ◽  
Funding Source ◽  
Organ Shortage ◽  
Number Of Patients ◽  
End Stage ◽  
Medical University

Abstract   Background, As a consequence of the worldwide increase in life expectancy and due to significant progress in the pharmacological and interventional treatment of heart failure (HF), the proportion of patients that reach an advanced phase of disease is steadily growing. Hence, more and more numerous group of patients is qualified to the heart transplantation (HT), whereas the number of potential heart donors has remained invariable since years. It contributes to deepening in disproportion between the demand for organs which can possibly be transplanted and number of patients awaiting on the HT list. Therefore, accurate identification of patients who are most likely to benefit from HT is imperative due to an organ shortage and perioperative complications. Purpose The aim of this study was to identify the factors associated with reduced survival during a 1.5-year follow-up in patients with end-stage HF awating HT. Method We propectively analysed 85 adult patients with end-stage HF, who were accepted for HT at our institution between 2015 and 2016. During right heart catheterization, 10 ml of coronary sinus blood was additionally collected to determine the panel of oxidative stress markers. Oxidative-antioxidant balance markers included glutathione reductase (GR), glutathione peroxidase (GPx), glutathione transferase (GST), superoxide dismutase (SOD) and its mitochondrial isoenzyme (MnSOD) and cytoplasmic (Cu/ZnSOD), catalase (CAT), malondialdehyde (MDA), hydroperoxides lipid (LPH), lipofuscin (LPS), sulfhydryl groups (SH-), ceruloplasmin (CR). The study protocol was approved by the ethics committee of the Medical University of Silesia in Katowice. The endpoint of the study was mortality from any cause during a 1.5 years follow-up. Results The median age of the patients was 53.0 (43.0–56.0) years and 90.6% of them were male. All included patients were treated optimally in accordance with the guidelines of the European Society of Cardiology. Mortality rate during the follow-up period was 40%. Multivariate logistic regression analysis showed that ceruloplasmin (odds ratio [OR] = 0.745 [0.565–0.981], p=0.0363), catalase (OR = 0.950 [0.915–0.98], p=0.0076), as well as high creatinine levels (OR = 1.071 [1.002–1.144], p=0.0422) were risk factors for death during 1.5 year follow-up. Conclusions Coronary sinus lower ceruloplasmin and catalase levels, as well as higher creatinine level are independently associated with death during 1.5 year follow-up. Funding Acknowledgement Type of funding source: Public Institution(s). Main funding source(s): Medical University of SIlesia, Katowice, POland

170 Heart Transplantation in 11 Patients with End Stage Heart Failure Caused by Muscular Dystrophy

2012 ◽  
Vol 31 (4) ◽  
pp. S66
Author(s):  
U. Fuchs ◽  
U. Schulz ◽  
B. Schulze ◽  
A. Zittermann ◽  
K. Hakim-Meibodi ◽  
...  
Keyword(s):  
Heart Failure ◽  
Muscular Dystrophy ◽  
Heart Transplantation ◽  
End Stage Heart Failure ◽  
End Stage

Deloading of the Left Ventricle by Ventricular Assist Device Normalizes Increased Expression of Endothelin ET A Receptors But Not Endothelin-Converting Enzyme-1 in Patients With End-Stage Heart Failure

Circulation ◽  
2000 ◽  
Vol 102 (suppl_3) ◽  
Author(s):  
Henning Morawietz ◽  
Marten Szibor ◽  
Winfried Goettsch ◽  
Babett Bartling ◽  
Matthias Barton ◽  
...  
Keyword(s):  
Heart Failure ◽  
Heart Transplantation ◽  
Ace Inhibitor ◽  
Ventricular Myocardium ◽  
Left Ventricular ◽  
Left Ventricular Myocardium ◽  
Converting Enzyme ◽  
Ventricular Assist ◽  
End Stage Heart Failure ◽  
End Stage

Background —Ventricular assist devices (VAD) are implanted in patients with end-stage heart failure for bridging the time until heart transplantation, resulting in hemodynamic unloading of the failing heart, improved cardiac contractile and mitochondrial function, and reversal of cardiac hypertrophy. It is unknown whether VAD unloading may affect the cardiac endothelin (ET) system, which has been proposed as one of the putative pathomechanisms of heart failure. Methods and Results —With the use of standard-calibrated, competitive reverse-transcription–polymerase chain reaction mRNA expression of components of the ET system was analyzed in left ventricular myocardium from nonfailing donor hearts, from failing hearts without and with ACE inhibitor therapy, and from patients with end-stage heart failure at the time of VAD implantation and 103±15 days after VAD implantation during removal with subsequent heart transplantation. ET receptor A (ET A ) was markedly upregulated in failing human myocardium. This increased ET A expression was not affected by ACE inhibitor treatment but was normalized by VAD unloading. ET A expression before or after VAD implantation did not correlate with duration of VAD implantation or suppression of Pro-ANP mRNA. ET B mRNA expression was unaffected by heart failure or VAD. In contrast, increased ET-converting enzyme-1 mRNA and ET-1 peptide levels in failing myocardium were partially normalized by ACE inhibition but not by VAD unloading. Conclusions —We conclude that VAD implantation normalizes ET A expression in failing human left ventricular myocardium, probably as the result of the beneficial effects of VAD unloading.

Heart Transplantation for End-Stage Heart Failure Due to Cardiac Sarcoidosis

2013 ◽  
Vol 45 (6) ◽  
pp. 2384-2386 ◽  
Author(s):  
D. Perkel ◽  
L.S.C. Czer ◽  
R.P. Morrissey ◽  
A. Ruzza ◽  
M. Rafiei ◽  
...  
Keyword(s):  
Heart Failure ◽  
Heart Transplantation ◽  
Cardiac Sarcoidosis ◽  
End Stage Heart Failure ◽  
End Stage

scholarly journals Medium term results following heart transplantation for end stage heart failure: A single center experience of 257 patients

2020 ◽  
Vol 72 (6) ◽  
pp. 524-534
Author(s):  
K.R. Balakrishnan ◽  
K.G. Sureshrao ◽  
R. Ravikumar ◽  
T. Muralikrishna ◽  
K. Ganapathy Subramaniam ◽  
...  
Keyword(s):  
Heart Failure ◽  
Heart Transplantation ◽  
Single Center ◽  
Medium Term ◽  
Single Center Experience ◽  
End Stage Heart Failure ◽  
End Stage

scholarly journals Catheter ablation for atrial fibrillation in patients with end‐stage heart failure and eligibility for heart transplantation

2020 ◽  
Author(s):  
Christian Sohns ◽  
Nassir F. Marrouche ◽  
Angelika Costard‐Jäckle ◽  
Samuel Sossalla ◽  
Leonard Bergau ◽  
...  
Keyword(s):  
Heart Failure ◽  
Atrial Fibrillation ◽  
Catheter Ablation ◽  
Heart Transplantation ◽  
End Stage Heart Failure ◽  
End Stage
Sign in / Sign up

Export Citation Format

Share Document